New blindness treatment moves closer to market
November 28, 2006Sales and Marketing AMD, Lucentis, Novartis
Patients suffering from the leading cause of blindness could soon benefit from a new treatment after it gained preliminary approval …
Byetta receives EU approval for Type II diabetes
November 28, 2006Sales and Marketing diabetes
Lilly and Amylin's new diabetes treatment, Byetta, has won EU approval.It is the first in a new class of anti-diabetic …
Bayer beats predictions in third quarter results
November 28, 2006Sales and Marketing
German drug and chemicals company Bayer is forecasting full-year sales of around €30 billion for 2006, following better-than-predicted third quarter …
Can pharma help the NHS to change?
November 27, 2006Sales and Marketing NHS, healthcare, industry relations, strategy
If there has been one constant during the 58 years of the NHS, it has been change - continuous, relentless …
Merck looks to traditional medicine in cancer research
November 20, 2006Research and Development
Merck is to collaborate with traditional medicine company Chi-Med to develop new small molecule anti-cancer drugs from natural products.Chi-Med, based …
A fresh perspective on your business
November 20, 2006Sales and Marketing consultants, marketing
A consultant is someone who borrows your watch to tell you the time- a cynical view of the role of …
Sanofi-Aventis to collaborate with French biotech company on Alzheimer’s disease
November 20, 2006Research and Development
Pharma company Sanofi-Aventis has entered into a research agreement with a major French biotech firm to study the role of …
NICE to say no to Tarceva
November 17, 2006Sales and Marketing NICE, Tarceva
Roche's new lung cancer treatment Tarceva looks set to be refused recommendation from NICE.Tarceva (erlotinib) is the first next-generation treatment …
Future global R&D for Bayer Schering defined
November 17, 2006Research and Development
Following the merger deal between German pharma companies Bayer and Schering earlier this year, the new corporation has unveiled radical …
Sanofi-Aventis to expand diabetes and thrombosis work with Euro RSCG
November 17, 2006Medical Communications
Sanofi-Aventis has retained the agency Euro RSCG Life to promote two of its major brands around the world, insulin analogue …
NICE to face judicial review over Alzheimer’s drug decision
November 17, 2006Legal action is to be taken against NICE over its decision to withdraw approval for NHS drugs for mild and …
Surprise delay for Novartis’ Galvus
November 15, 2006Sales and Marketing Galvus, diabetes
The FDA will take three months longer than expected to review Novartis' new diabetes treatment, Galvus, after the pharma company …
Trained to win
November 13, 2006Business Services, Sales and Marketing marketing, sales, training
Pharmaceutical sales and marketing managers have a dizzying array of training courses, educational aids and events at their disposal, all …
Genentech to buy biotech Tanox for $900 million
November 10, 2006Sales and Marketing Genentech
Genentech is to pay $919 million for Tanox, a biotech company which specialises in monoclonal antibodies.Genentech has been working with …
iPod-ready patient information leaflets coming soon
November 10, 2006Sales and Marketing patients
From next month, patients will be able to learn about their medicines by listening to an iPod, MP3 player or …
Roche sponsor early breast cancer leaflet
November 10, 2006Medical Communications
Roche is backing a new leaflet designed to help patients with newly diagnosed early breast cancer make sense of the …
US Democrats to target pharmaceutical prices
November 10, 2006Sales and Marketing
The decisive victory of the Democrat party in the US mid-term elections looks set to bring new pressure on pharmaceutical …
UK biotech comes to market
November 10, 2006Research and Development biotech, investment
At last, the signals are getting stronger that the biotechnology industry is poised and ready to tackle the publicly quoted …
Sepsis drug put back at least two years
November 9, 2006Research and Development
AstraZeneca is being forced to conduct a second phase II trial on its sepsis drug, CytoFab.This follows discussions with US, …
‘Pulsed’ vitamin D drug could transform advanced prostate cancer treatment
November 9, 2006Research and Development
American biotech company Novacea says it could be on the brink of revolutionising the prostate cancer market if phase III …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
